Filtered By:
Drug: Plavix
Procedure: Angioplasty
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 422 results found since Jan 2013.
Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients
CONCLUSION: Compared with prolonged DAPT, clopidogrel monotherapy showed similar long-term outcomes in patients at high-risk after second-generation DES implantation.PMID:33904262 | DOI:10.3346/jkms.2021.36.e106
Source: Journal of Korean Medical Science - April 27, 2021 Category: Biomedical Science Authors: Dong Yeon Kim Sung Woo Cho Kyu Tae Park Jong Hwa Ahn Taek Kyu Park Yong Ho Jang Ki Hong Choi Joo Myung Lee Jeong Hoon Yang Young Bin Song Jin Ho Choi Seung Hyuk Choi Hyeon Cheol Gwon Sang Hoon Lee Joo Yong Hahn Source Type: research
Impact of Transcatheter Aortic Valve Implantation on Thrombin Generation and Platelet Function
CONCLUSION: In this pilot study, we were able to demonstrate that thrombin generation is significantly increased early after TAVI, while platelet function is not affected. Increased thrombin concentrations may contribute to the high risk of postprocedural thromboembolic events. This leads to the hypothesis that extended peri-interventional anticoagulation early after TAVI may be an approach to reduce thromboembolic events.PMID:33759144 | DOI:10.1055/s-0041-1725190
Source: Thrombosis and Haemostasis - March 24, 2021 Category: Hematology Authors: Philipp Mourikis Lisa Dannenberg Saif Zako Carolin Helten Ren é M'Pembele Hannah Richter Thomas Hohlfeld Christian Jung Tobias Zeus Malte Kelm Verena Veulemans Amin Polzin Source Type: research
Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention: A systematic review and meta-analysis
CONCLUSION: DAPT may be shortened to 3 months in patients with low ischemic risk but high bleeding risk, whereas it may be extended to >12 months in case of high ischemic and low bleeding risk. The concept of P2Y12 inhibitor monotherapy, although promising, needs to be challenged.PROSPERO REGISTRATION NO: CRD42020163719.PMID:33753284 | DOI:10.1016/j.vph.2021.106858
Source: Vascular Pharmacology - March 23, 2021 Category: Drugs & Pharmacology Authors: Georg Gelbenegger Ummahan Erari-Canyurt J ürgen Grafeneder Bernd Jilma Maciej Lesiak Anna Komosa Raffaele de Caterina Marek Postula Jolanta M Siller-Matula Source Type: research
Reduced-Dose Prasugrel versus Clopidogrel for Patients Undergoing Percutaneous Coronary Intervention
Int Heart J. 2021 Mar 17. doi: 10.1536/ihj.20-508. Online ahead of print.ABSTRACTWhether reduced-dose prasugrel has a better efficacy or safety than standard-dose clopidogrel remains unknown in patients undergoing percutaneous coronary intervention (PCI).A systematic search of PubMed, EMBASE, Google Scholar, and Cochrane Library from database inception to May 1, 2020 was performed to compare the clinical outcomes in patients with acute coronary syndrome or stable coronary artery disease undergoing PCI between those treated with reduced-dose prasugrel and clopidogrel. The pooled odds ratio (OR) and 95% confidence interval (...
Source: International Heart Journal - March 18, 2021 Category: Cardiology Authors: Cheng-Han Lee Mu-Shiang Huang Ting-Hsing Chao Sheng-Hsiang Lin Yi-Heng Li Source Type: research
